Oncolytics Biotech Inc., of Calgary, Alberta, said it completed patient enrollment in its U.S. Phase II trial testing intravenous administration of oncolytic virus Reolysin in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter